Catalent to Present at Pep Talk 2009 Protein Expression Conference
Released
on:January 9, 2009, 9:32 am
Press Release Author: Dan Dunlop
Industry: Biotech
Press Release Summary: Dr. Greg Bleck, the senior director of cell line engineering
at Catalent Pharma Solutions, will present at the 12th Annual Pep Talk 2009 Protein
Expression Conference to be held in San Diego, C.A., January 12-14, 2009. Dr.
Bleck’s presentation is titled “Consistent Development of Stable-High Expressing
Mammalian Cell Lines in Four Months Using GPEx®.”
Press Release Body: Research Triangle Park, N.C. – January 9, 2009 – Dr. Greg Bleck,
the senior director of cell line engineering at Catalent Pharma Solutions, will
present later this month at the 12th Annual Pep Talk 2009 Protein Expression
Conference to be held in San Diego, C.A., January 12-14, 2009. The conference
offers a strong scientific program with more than 120 presentations and poster
sessions reviewing the latest research and leading edge technologies in the field.
Dr. Bleck’s presentation is titled “Consistent Development of Stable-High Expressing
Mammalian Cell Lines in Four Months Using GPEx®.” Catalent’s proprietary GPEx®
method of cell line engineering generates high-expressing, genetically stable cells
for all mammalian cell types. Antibiotic selection is not needed as part of the
procedure; so multiple gene constructs can be added individually, at different gene
ratios without any requirement for antibiotic resistance markers. This allows
re-production of cellular pathways within these cell types as well as the ability to
easily add protein processing enzymes to an already established cell line. Specific
productivities of GPEx® antibody producing cell lines range from 30 -70
picograms/cell/day without upstream process development, while cell lines producing
non-antibody proteins as expected have a much broader range of productivities, but
if the protein has no secretion problems and does not inhibit cell growth, specific
productivities similar to antibodies are obtained.
About Catalent
Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of
advanced dose form and packaging technologies, and development, manufacturing and
packaging services for pharmaceutical, biotechnology and consumer health companies
in nearly 100 countries. Catalent applies its local market expertise and technical
creativity to advance treatments, change markets and enhance patient outcomes.
Catalent employs approximately 9,500 at more than 30 facilities worldwide and
generates more than $1.8 billion of annual revenue. For more information, visit
www.catalent.com.
###
Web Site: http://www.catalent.com
Contact Details: 104-A North Elliott Road
Chapel Hill, NC 27514
Phone: 919-929-0225
Fax: 919-968-8278
ddunlop@jenningsco.com
2012
